Immunotherapy is an exciting area for lung cancer, with numerous possibilities and game-changing potential. Speaking from the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland, Solange Peters, MD, PhD, of Lausanne University Hospital, Lausanne, France, discusses the future of immunotherapy for non-small cell lung cancer (NSCLC). Prof. Peters highlights the recent Phase III PACIFIC trial (NCT02125461) of durvalumab, which produced outstanding progression-free survival results. She then emphasizes what immunotherapy developments she is most excited about.
Paradigm-changing immunotherapy for advanced NSCLC: the PACIFIC and beyond
